Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens
- 29 November 2016
- Vol. 49 (1) , 75-82
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutationsBMC Cancer, 2015
- Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytologyScientific Reports, 2015
- Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation SequencingAmerican Journal of Clinical Pathology, 2015
- Pragmatic issues in biomarker evaluation for targeted therapies in cancerNature Reviews Clinical Oncology, 2014
- Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genesBMC Genomics, 2014
- ACMG clinical laboratory standards for next-generation sequencingGenetics in Medicine, 2013
- Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome ResistanceAnnals of Surgical Oncology, 2009
- Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancerAnnals of Oncology, 2003